Home » Topics » BioWorld Science

BioWorld Science
RSS

New peripheral 5-HT2A antagonists for NAFLD treatment by structural modification of pimavanserin

June 19, 2020

Phase I data presented for PF-06882961 in patients with type 2 diabetes

June 19, 2020

New androgen and/or glucocorticoid receptor antagonists synthesized at Nuvation Bio

June 19, 2020

Bristol-Myers Squibb patents FPR1/FPR2 agonists

June 19, 2020

Nimbus Lakshmi identifies new TYK2 inhibitors

June 19, 2020

Merck & Co. discovers adenosine receptor A2A and/or A2B antagonists

June 19, 2020

Mutations in GBF1 associated with hereditary motor neuropathy

June 19, 2020

Novel humanized immunocompetent mouse model to study DCP-001 vaccine

June 19, 2020

SETD2 as biomarker of overall survival in systemic mastocytosis

June 19, 2020

Positive topline phase II data for XP-3924 in type 1 diabetes mellitus

June 19, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...